Study #2022-0800
A phase 1/1b, open-label, dose-finding, first-in-human study to evaluate the safety and antitumor activity of CX-904, an EGFR-targeted T-cell Engager in advanced solid tumors (CTMX-904-101)
MD Anderson Study Status
Not Accepting
Treatment Agent
CX-904
Description
The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumors
Study phase:
Phase I
Physician name:
George Blumenschein
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-302-5084
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.